Showing results (41-50 of 72) with videos related to
Sort By:
Pageof 8
Antimicrobial Agents and Chemotherapy|January 9, 2013
Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expressionC Vinot, L Gavard, J M Tréluyer, et al.Antimicrobial Agents and Chemotherapy|April 8, 2015
Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancyJ B Pain, M P Lê, M Caseris, et al.Journal of Clinical Microbiology|January 7, 2005
Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitorsF Damond, F Brun-Vezinet, S Matheron, et al.HIV Medicine|May 26, 2010
Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patientsS Lambert-Niclot, N Machouf, G Peytavin, et al.HIV Medicine|July 16, 2008
Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke TrialM A Valantin, E Lanoy, M Bentata, et al.Antimicrobial Agents and Chemotherapy|February 26, 2004
Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia modelE Azoulay-Dupuis, J P Bédos, J Mohler, et al.Antimicrobial Agents and Chemotherapy|April 25, 2012
Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 studyC Clavel, G Peytavin, R Tubiana, et al.The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 25, 2019
Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosisS Perrineau, M Lachâtre, M P Lê, et al.HIV Clinical Trials|November 9, 2012
Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra studyL Schneider, N Ktorza, S Fourati, et al.HIV Medicine|July 25, 2008
Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot studyH Ait-Mohand, M Bonmarchand, M Guiguet, et al.Pageof 8